Brief: Lumos Pharma Reports Qtrly Loss Per Share $0.65
13/08/2020 21:45
Aug 13 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA REPORTS SECOND QUARTER 2020 RESULTS AND
PROVIDES
UPDATE ON CLINICAL AND CORPORATE ACTIVITIES
* LUMOS PHARMA INC - REAFFIRMS ITS EXPECTATION OF INITIATION
OF
ITS PHASE 2B LUM-201 TRIAL IN PEDIATRIC GROWTH HORMONE
DEFICIENCY
* LUMOS PHARMA INC - QTRLY LOSS PER SHARE $0.65
Source text for Eikon: ID:nGNX41pG1z
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)